BENGALURU (Reuters) – Indian drugmaker Strides Pharma Science said on Friday its unit Stelis Biopharma has partnered with the Russian Direct Investment Fund to produce and supply at least 200 million doses of the Sputnik V COVID-19 vaccine.
(Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Arun Koyyur)
